- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
Patent holdings for IPC class A61K 31/5386
Total number of patents in this class: 1099
10-year publication summary
|
59
|
47
|
49
|
74
|
91
|
81
|
84
|
118
|
205
|
95
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2714 |
21 |
| Boehringer Ingelheim International GmbH | 4501 |
19 |
| Chugai Seiyaku Kabushiki Kaisha | 1412 |
19 |
| Merck Sharp & Dohme LLC | 3728 |
18 |
| Bristol-myers Squibb Company | 4721 |
17 |
| Genentech, Inc. | 4101 |
15 |
| Pfizer Inc. | 3384 |
15 |
| Arvinas Operations, Inc. | 262 |
15 |
| Bayer AG | 3488 |
14 |
| Gilead Sciences, Inc. | 2219 |
14 |
| Repare Therapeutics, Inc. | 59 |
13 |
| Vertex Pharmaceuticals Incorporated | 1587 |
12 |
| Kymera Therapeutics, Inc. | 260 |
12 |
| Merck Patent GmbH | 5725 |
11 |
| Bayer Pharma AG | 1015 |
11 |
| Revolution Medicines, Inc. | 328 |
11 |
| Novartis AG | 10300 |
10 |
| Amgen Inc. | 4425 |
10 |
| Mirati Therapeutics, Inc. | 286 |
10 |
| Universite de Montreal | 350 |
9 |
| Other owners | 823 |